Accrued external research and development expenses
14,324
12,137
11,451
7,705
Other accrued expenses
8,881
6,827
15,561
11,115
Operating lease liabilities, current
315
419
611
656
Total current liabilities
30,360
31,142
36,641
26,744
Principal term loan balance
60,000
30,000
30,000
30,000
Unamortized debt discount and issuance costs
1,400
1,254
1,351
1,450
Accrued end of term fee
740
619
510
398
Long-term debt, net
59,340
29,365
29,159
28,948
Operating lease liabilities, non-current
1,207
1,277
1,253
1,373
Total liabilities
90,907
61,784
67,053
57,065
Common stock, 0.0001 par value 100,000,000 shares authorized as of june 30, 2026 and december 31, 2025 38,345,666 and 37,890,616 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
4
4
4
4
Additional paid-in capital
1,278,990
1,262,686
1,249,043
1,022,324
Accumulated other comprehensive (loss) income
-1,608
-571
965
718
Accumulated deficit
-633,222
-573,690
-510,186
-449,655
Total stockholders' equity
644,164
688,429
739,826
573,391
Total liabilities and stockholders' equity
735,071
750,213
806,879
630,456
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.